|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2400091732 |
|
最近更新日期: Date of Last Refreshed on: |
2024-11-01 16:51:57 |
|
注册时间: Date of Registration: |
2024-11-01 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
肌红蛋白水平与心脏术后14天死亡率 |
|
Public title: |
Serum Myoglobin after Cardiac Surgery and 14-Day Mortality |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
肌红蛋白(Myoglobin)与心脏术后早期疗效的研究 |
|
Scientific title: |
Serum Myoglobin after Cardiac Surgery and short-term outcomes |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
刘佳升 |
研究负责人: |
区景松 |
|
Applicant: |
Liu Jiasheng |
Study leader: |
Ou Jingsong |
|
申请注册联系人电话: Applicant telephone: |
+86 13708238995 |
研究负责人电话: Study leader's telephone: |
+86 13631462338 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
578946994@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
oujs@mail.sysu.edu.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
广州市中山二路58号 |
研究负责人通讯地址: |
广州市中山二路58号 |
|
Applicant address: |
No. 58 Zhongshan 2nd Road, Guangzhou |
Study leader's address: |
No. 58 Zhongshan 2nd Road, Guangzhou |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
中山大学附属第一医院 |
||
|
Applicant's institution: |
the First Affiliated Hospital, Sun Yat-sen University |
||
|
研究负责人所在单位: |
中山大学附属第一医院 |
||
|
Affiliation of the Leader: |
The First Affiliated Hospital, Sun Yat-sen University |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
伦审临[2024]297 号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
中山大学附属第一医院临床科研和实验动物伦理委员会 |
||
|
Name of the ethic committee: |
IEC for Clinical Research and Animal Trials of the First Affiliated Hospital, Sun Yat-sen University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-05-24 00:00:00 |
||
|
伦理委员会联系人: |
陈湛勇 |
||
|
Contact Name of the ethic committee: |
Chen ZhanYong |
||
|
伦理委员会联系地址: |
广州市中山二路58号 |
||
|
Contact Address of the ethic committee: |
No. 58 Zhongshan 2nd Road, Guangzhou |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 20 87334871 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
chenzhy233@mail.sysu.edu.cn |
|
研究实施负责(组长)单位: |
中山大学附属第一医院 |
||||||||||||||||||||||
|
Primary sponsor: |
The First Affiliated Hospital,Sun Yat-sen University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
广州市中山二路58号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 58 Zhongshan 2nd Road, Guangzhou |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
国家自然科学基金资助项目(92268202,82270485);中国医学科学院非营利性中央研究院基金(2023-PT320-03);国家重点研发计划项目(2021YFA0805100);广东省科技计划项目(2023B1212060018);中山大学临床研究5010项目 |
||||||||||||||||||||||
|
Source(s) of funding: |
National Natural Science Foundation of China (92268202, 82270485);Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences (2023-PT320-03);National Key R&D Program of China (2021YFA0805100);The Science and Technology Planning Project of Guangdong Province (2023B1212060018);Sun Yat-sen University Clinical Research 5010 Program |
||||||||||||||||||||||
|
Target disease: |
cardiac disease |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
回顾性研究 | ||||||||||||||||||||||
|
Study phase: |
Retrospective study |
||||||||||||||||||||||
|
研究设计: |
横断面 |
||||||||||||||||||||||
|
Study design: |
Cross-sectional |
||||||||||||||||||||||
|
研究目的: |
明确肌红蛋白与体外循环心脏手术患者术后短期疗效术后短期疗效的关系 |
||||||||||||||||||||||
|
Objectives of Study: |
The objective is to determine the relationship between postoperative myoglobin levels and the short-termoutcomes of cardiac surgery. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.年龄大于等于18岁; 2.接受体外循环心脏手术; |
||||||||||||||||||||||
|
Inclusion criteria |
1.aged ≥18 years old; 2.underwent cardiopulmonary bypass cardiac surgery; |
||||||||||||||||||||||
|
排除标准: |
1.术前有肾功能不全,定义为术前血清肌酐大于 176 μ mol/L 或需要肾脏替代治疗; 2.术前有急性心力衰竭(AHF)和急性心肌梗死(AMI); 3.术后 24h 死 亡; 4.病历不完整者; |
||||||||||||||||||||||
|
Exclusion criteria: |
1.had preoperative renal dysfunction, defined as serum creatine before surgery greater than 176 μmol/L or a requirement for renal replacement therapy; 2.had preoperative acute heart failure(AHF) and acute myocardial infraction(AMI); 3.died in 24h after operation; 4.incomplete medical records; |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-06-01 00:00:00至 To 2024-10-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2024-06-01 00:00:00 至 To 2024-08-15 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
结束 /Completed |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
无 |
|
Blinding: |
None |
|
是否共享原始数据: IPD sharing |
No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
发表文章后;邮件联系 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
After publishing the paper;Contact by email |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
CRF |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
CRF |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |